Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
6.00
+0.08 (1.35%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Tango Therapeutics Revenue
Tango Therapeutics had revenue of $19.88M in the quarter ending June 30, 2024, with 36.15% growth. This brings the company's revenue in the last twelve months to $42.51M, up 26.16% year-over-year. In the year 2023, Tango Therapeutics had annual revenue of $36.53M with 46.93% growth.
Revenue (ttm)
$42.51M
Revenue Growth
+26.16%
P/S Ratio
14.79
Revenue / Employee
$303,636
Employees
140
Market Cap
642.87M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 36.53M | 11.67M | 46.93% |
Dec 31, 2022 | 24.86M | -12.18M | -32.89% |
Dec 31, 2021 | 37.04M | 29.39M | 383.83% |
Dec 31, 2020 | 7.66M | -16.99M | -68.94% |
Dec 31, 2019 | 24.65M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Ironwood Pharmaceuticals | 400.57M |
Avid Bioservices | 142.36M |
Standard BioTools | 136.30M |
Y-mAbs Therapeutics | 86.55M |
IRADIMED CORPORATION | 69.48M |
Exscientia | 26.57M |
Stoke Therapeutics | 15.16M |
ABIVAX Société Anonyme | 9.68M |
TNGX News
- 7 weeks ago - Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data - Seeking Alpha
- 2 months ago - Tango Therapeutics to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights - Business Wire
- 5 months ago - Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 5 months ago - Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program - PRNewsWire
- 5 months ago - Tango Therapeutics to stop development of cancer therapy - Reuters
- 5 months ago - Tango Therapeutics Announces Discontinuation of TNG348 Program - Business Wire
- 6 months ago - Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights - Business Wire